药明康德
(603259)
| 流通市值：2732.73亿 | | | 总市值：3296.75亿 |
| 流通股本：24.73亿 | | | 总股本：29.84亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 12,435,776,568.29 | 45,456,165,774.18 | 32,856,716,508.86 | 20,799,281,882.46 |
| 营业收入 | 12,435,776,568.29 | 45,456,165,774.18 | 32,856,716,508.86 | 20,799,281,882.46 |
| 二、营业总成本 | 7,433,446,073.33 | 29,148,154,763.35 | 21,256,267,707.67 | 14,014,556,298.92 |
| 营业成本 | 6,167,822,778.36 | 23,801,434,557.94 | 17,538,098,637.79 | 11,554,124,208.9 |
| 税金及附加 | 92,179,839.85 | 361,477,739.23 | 273,965,204.62 | 170,017,517.84 |
| 销售费用 | 182,056,633.56 | 806,867,421.28 | 569,374,574.48 | 394,367,252.66 |
| 管理费用 | 709,748,017.05 | 2,660,731,035.82 | 1,858,526,669.26 | 1,175,416,378.21 |
| 研发费用 | 266,956,709.12 | 1,119,452,992.76 | 825,650,523.1 | 514,427,140.15 |
| 财务费用 | 14,682,095.39 | 398,191,016.32 | 190,652,098.42 | 206,203,801.16 |
| 其中:利息费用 | 30,952,924.14 | 268,379,352.78 | 226,711,873.66 | 146,262,529.53 |
| 其中:利息收入 | 274,983,078.16 | 938,021,864.11 | 678,141,337.63 | 444,165,181 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 459,260,746.85 | -137,097,911.32 | -34,435,917.65 | -182,183,014.07 |
| 加:投资收益 | 164,837,080.44 | 8,588,017,064.9 | 4,098,539,874.75 | 3,669,213,003.27 |
| 资产处置收益 | 2,162,406.4 | -58,067,020.13 | -69,873,339.23 | -12,844,822.74 |
| 资产减值损失(新) | -41,177,323.17 | -541,555,966.37 | -410,113,443.18 | -321,420,123.36 |
| 信用减值损失(新) | -63,930,643.66 | -527,962,030.16 | -346,855,872.7 | -189,218,242.77 |
| 其他收益 | 91,453,793.37 | 298,738,643.85 | 228,351,689.81 | 182,845,973.63 |
| 四、营业利润 | 5,614,936,555.19 | 23,930,083,791.6 | 15,066,061,792.99 | 9,931,118,357.5 |
| 加:营业外收入 | 6,577,970.54 | 31,398,314.78 | 12,551,180.53 | 7,692,961.06 |
| 减:营业外支出 | 14,234,269.52 | 55,330,859.93 | 41,544,623.08 | 31,394,760.59 |
| 五、利润总额 | 5,607,280,256.21 | 23,906,151,246.45 | 15,037,068,350.44 | 9,907,416,557.97 |
| 减:所得税费用 | 936,766,274.88 | 4,573,085,354.19 | 2,830,874,889.18 | 1,247,068,437.43 |
| 六、净利润 | 4,670,513,981.33 | 19,333,065,892.26 | 12,206,193,461.26 | 8,660,348,120.54 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 4,652,597,022.26 | 17,977,669,327.23 | 12,339,724,609.74 | 8,791,888,321.78 |
| 终止经营净利润 | 17,916,959.07 | 1,355,396,565.03 | -133,531,148.48 | -131,540,201.24 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 4,651,517,987.76 | 19,150,582,400.69 | 12,075,512,956.92 | 8,560,882,627.56 |
| 少数股东损益 | 18,995,993.57 | 182,483,491.57 | 130,680,504.34 | 99,465,492.98 |
| 扣除非经常损益后的净利润 | 4,275,624,429.82 | 13,240,556,954.42 | 9,522,413,145.23 | 5,582,126,598.19 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.59 | 6.7 | 4.25 | 3.01 |
| (二)稀释每股收益 | 1.58 | 6.61 | 4.21 | 2.99 |
| 八、其他综合收益 | -273,737,529.63 | -449,776,946.3 | -95,953,157.33 | -37,885,690.49 |
| 归属于母公司股东的其他综合收益 | -268,621,140.23 | -447,995,390.63 | -84,806,802.74 | -32,103,995.36 |
| 九、综合收益总额 | 4,396,776,451.7 | 18,883,288,945.96 | 12,110,240,303.93 | 8,622,462,430.05 |
| 归属于母公司股东的综合收益总额 | 4,382,896,847.53 | 18,702,587,010.06 | 11,990,706,154.18 | 8,528,778,632.2 |
| 归属于少数股东的综合收益总额 | 13,879,604.17 | 180,701,935.9 | 119,534,149.75 | 93,683,797.85 |
| 公告日期 | 2026-04-28 | 2026-03-24 | 2025-10-27 | 2025-07-29 |
| 审计意见(境内) | | 标准无保留意见 | | |